Stock listing
Euronext:ADOC Adocia SA Action
Home listing (Euronext) of Adocia SA
Follow Adocia SA into a list and get an email when it puts out news.
Share price · EURONEXT:ADOC
€3.29 EUR -0.24 (-6.7%)
Close on Nov 20, 2026
- Day range
- €3.26 – €3.49 EURNov 20, 2026
- Volume
- 311,387 sharesNov 20, 2026
- Market cap
- €72.26M EURAt the close on Nov 20, 2026 · price × 21.94M shares outstanding
- 52-week range
- €2.01 – €8.61 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €1.11M EURMedian day 133,417 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:ADOC · Home | €3.294 EUR | -0.238 (-6.7%) | 311,387 | €3.46 | €3.492 | €3.258 | €3.532 | Close on Nov 20, 2026 |
| LSE:0QAI | €3.36 EUR | -0.316 (-8.6%) | 736 | €3.47 | €3.47 | €3.36 | €3.676 | Close on Nov 20, 2026 |
| Frankfurt:A89 | €3.36 EUR | -0.17 (-4.8%) | — | €3.36 | €3.36 | €3.36 | €3.53 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · EURONEXT:ADOC · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €3.294 | -0.238 | -6.7% | €3.46 | €3.492 | €3.258 | 311,387 | |
| €3.532 | -0.26 | -6.9% | €3.92 | €3.95 | €3.51 | 603,126 | |
| €3.792 | -0.428 | -10.1% | €4.064 | €4.064 | €3.764 | 684,987 | |
| €4.22 | -0.454 | -9.7% | €4.698 | €4.76 | €4.22 | 998,508 | |
| €4.674 | +0.37 | +8.6% | €4.20 | €5.20 | €4.15 | 1,781,701 | |
| €4.304 | -0.076 | -1.7% | €4.40 | €4.576 | €4.10 | 927,933 | |
| €4.38 | +0.58 | +15.3% | €3.852 | €4.60 | €3.804 | 2,007,148 | |
| €3.80 | +0.76 | +25.0% | €3.12 | €3.98 | €3.12 | 1,627,757 | |
| €3.04 | +0.288 | +10.5% | €2.752 | €3.04 | €2.726 | 218,432 | |
| €2.752 | -0.09 | -3.2% | €2.828 | €2.828 | €2.746 | 106,872 | |
| €2.842 | +0.014 | +0.5% | €2.844 | €2.946 | €2.782 | 164,749 | |
| €2.828 | -0.102 | -3.5% | €2.92 | €2.972 | €2.752 | 313,512 | |
| €2.93 | -0.19 | -6.1% | €3.10 | €3.10 | €2.822 | 492,634 | |
| €3.12 | +0.092 | +3.0% | €2.902 | €3.338 | €2.86 | 435,323 | |
| €3.028 | -0.032 | -1.0% | €3.30 | €3.384 | €3.028 | 834,037 | |
| €3.06 | -0.062 | -2.0% | €3.238 | €3.45 | €3.026 | 627,281 | |
| €3.122 | +0.408 | +15.0% | €2.82 | €3.34 | €2.788 | 993,457 | |
| €2.714 | +0.258 | +10.5% | €2.46 | €2.714 | €2.432 | 313,953 | |
| €2.456 | +0.058 | +2.4% | €2.38 | €2.55 | €2.318 | 211,529 | |
| €2.398 | -0.032 | -1.3% | €2.428 | €2.48 | €2.378 | 90,889 | |
| €2.43 | +0.07 | +3.0% | €2.34 | €2.442 | €2.324 | 167,515 | |
| €2.36 | -0.086 | -3.5% | €2.468 | €2.60 | €2.34 | 438,047 | |
| €2.446 | +0.174 | +7.7% | €2.24 | €2.464 | €2.148 | 526,384 | |
| €2.272 | -0.038 | -1.6% | €2.232 | €2.30 | €2.22 | 139,089 | |
| €2.31 | -0.26 | -10.1% | €2.60 | €2.60 | €2.282 | 619,637 | |
| €2.57 | +0.40 | +18.4% | €2.204 | €2.62 | €2.194 | 503,601 | |
| €2.17 | +0.15 | +7.4% | €2.068 | €2.17 | €2.024 | 130,842 | |
| €2.02 | -0.068 | -3.3% | €2.09 | €2.13 | €2.02 | 90,581 | |
| €2.088 | +0.034 | +1.7% | €2.07 | €2.09 | €2.02 | 103,879 | |
| €2.054 | +0.044 | +2.2% | €2.04 | €2.178 | €2.034 | 167,363 | |
| €2.01 | -0.056 | -2.7% | €2.08 | €2.094 | €2.01 | 95,506 | |
| €2.066 | -0.034 | -1.6% | €2.12 | €2.12 | €2.05 | 99,663 | |
| €2.10 | -0.03 | -1.4% | €2.16 | €2.22 | €2.08 | 113,144 | |
| €2.13 | -0.016 | -0.7% | €2.148 | €2.25 | €2.126 | 139,889 | |
| €2.146 | -0.104 | -4.6% | €2.25 | €2.302 | €2.11 | 298,083 | |
| €2.25 | -0.22 | -8.9% | €2.51 | €2.53 | €2.19 | 476,037 | |
| €2.47 | -0.206 | -7.7% | €2.678 | €2.678 | €2.412 | 412,895 | |
| €2.676 | +0.048 | +1.8% | €2.654 | €2.83 | €2.634 | 253,113 | |
| €2.628 | +0.008 | +0.3% | €2.63 | €2.686 | €2.546 | 306,349 | |
| €2.62 | -0.87 | -24.9% | €3.12 | €3.12 | €2.534 | 1,064,685 | |
| €3.49 | -0.044 | -1.2% | €3.50 | €3.55 | €3.48 | 44,766 | |
| €3.534 | -0.076 | -2.1% | €3.61 | €3.678 | €3.534 | 62,058 | |
| €3.61 | +0.028 | +0.8% | €3.592 | €3.61 | €3.52 | 62,153 | |
| €3.582 | -0.068 | -1.9% | €3.65 | €3.65 | €3.554 | 40,938 | |
| €3.65 | -0.018 | -0.5% | €3.66 | €3.79 | €3.64 | 42,096 | |
| €3.668 | +0.064 | +1.8% | €3.61 | €3.70 | €3.594 | 46,136 | |
| €3.604 | -0.06 | -1.6% | €3.668 | €3.668 | €3.598 | 67,707 | |
| €3.664 | +0.118 | +3.3% | €3.54 | €3.778 | €3.52 | 92,543 | |
| €3.546 | -0.102 | -2.8% | €3.628 | €3.628 | €3.474 | 104,821 | |
| €3.648 | -0.152 | -4.0% | €3.774 | €3.774 | €3.62 | 127,275 | |
| €3.80 | -0.08 | -2.1% | €3.90 | €3.954 | €3.764 | 85,178 | |
| €3.88 | -0.052 | -1.3% | €3.95 | €3.96 | €3.88 | 30,692 | |
| €3.932 | -0.024 | -0.6% | €3.952 | €3.952 | €3.88 | 80,528 | |
| €3.956 | -0.044 | -1.1% | €4.00 | €4.00 | €3.92 | 51,512 | |
| €4.00 | -0.128 | -3.1% | €4.12 | €4.12 | €4.00 | 37,883 | |
| €4.128 | +0.004 | +0.1% | €4.12 | €4.13 | €4.02 | 71,464 | |
| €4.124 | +0.106 | +2.6% | €4.02 | €4.17 | €3.98 | 112,895 | |
| €4.018 | +0.03 | +0.8% | €4.00 | €4.018 | €3.92 | 55,333 | |
| €3.988 | -0.008 | -0.2% | €3.994 | €4.02 | €3.96 | 46,017 | |
| €3.996 | -0.016 | -0.4% | €4.02 | €4.068 | €3.996 | 31,732 | |
| €4.012 | +0.032 | +0.8% | €4.00 | €4.05 | €3.98 | 37,398 | |
| €3.98 | -0.03 | -0.7% | €4.00 | €4.09 | €3.956 | 90,232 | |
| €4.01 | -0.05 | -1.2% | €4.06 | €4.10 | €3.94 | 135,991 | |
| €4.06 | -0.11 | -2.6% | €4.14 | €4.14 | €4.00 | 112,351 | |
| €4.17 | +0.048 | +1.2% | €4.12 | €4.184 | €4.064 | 74,576 | |
| €4.122 | -0.112 | -2.6% | €4.25 | €4.27 | €4.102 | 109,533 |
- Ticker
- Euronext:ADOC
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Euronext
- Currency
- EUR
What changed lately
Latest news release · Nov 16, 2026
ADOCIA Presents Preclinical Data at ObesityWeek® 2026 Confirming the Potential of AdoXLong™ for Monthly Injections of Peptides
Latest deck · Nov 2, 2026
Q3 2026 Earnings Presentation
Earnings · 19 slides
Latest news
ADOCIA Presents Preclinical Data at ObesityWeek® 2026 Confirming the Potential of AdoXLong™ for Monthly Injections of Peptides
Nov 16, 2026
Closed €4.22 (-9.7%) on Nov 16, 2026
ADOCIA to Present Preclinical Data from its AdoXLong™ Platform at ObesityWeek® 2026
Nov 9, 2026
Closed €3.80 (+25.0%) on Nov 10, 2026
Number of Shares and Voting Rights of ADOCIA as of October 31, 2026
Nov 6, 2026
Closed €2.75 (-3.2%) on Nov 6, 2026
ADOCIA Reports Third Quarter 2026 Financial Results and Provides a Business Update
Oct 29, 2026
Closed €3.03 (-1.0%) on Oct 30, 2026
ADOCIA Announces a €7 Million Financing and the Extension of Its Cash Runway to 2028
Oct 20, 2026
Closed €2.45 (+7.7%) on Oct 20, 2026
Number of Shares and Voting Rights of ADOCIA as of September 30, 2026
Oct 9, 2026
Closed €2.05 (+2.2%) on Oct 9, 2026
ADOCIA Reports First Half 2026 Financial Results and Provides a Business Update
Sep 24, 2026
Closed €2.62 (-24.9%) on Sep 25, 2026
ADOCIA Announces Oral Presentations at EASD Annual Meeting and at Breakthrough T1D Clinical & Research Congress
Sep 17, 2026
Closed €3.65 (-0.5%) on Sep 18, 2026
Number of Shares and Voting Rights of ADOCIA as of August 31st, 2026
Sep 10, 2026
Closed €3.65 (-4.0%) on Sep 11, 2026
ADOCIA Announces Changes in its Board of Directors with the Appointment of a New Director and a Board Observer
Sep 1, 2026
Closed €4.12 (+2.6%) on Sep 2, 2026
Adocia SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 39 in all · newest Nov 16, 2026 · oldest 2025
- Decks
- 49 decks · latest Nov 2, 2026
Where Adocia SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:ADOC · Home listing · This page | Euronext | France | EUR |
| LSE:0QAI | LSE | United Kingdom | EUR |
| LS Exchange:A1JTC2 | LS Exchange | Germany | EUR |
| gettex:A89 | gettex | Germany | EUR |
| Tradegate:A89 | Tradegate | Germany | EUR |
| Lang & Schwarz:A1JTC2 | Lang & Schwarz | Germany | EUR |
| OTC:ADOCY | OTC | United States | USD |
| Aquis:ADOCP | Aquis | United Kingdom | EUR |
| Aquis:ADOCP | Aquis | United Kingdom | EUR |
| Dusseldorf:A89 | Dusseldorf | Germany | EUR |
| Frankfurt:A89 | Frankfurt | Germany | EUR |
| Hamburg:A89 | Hamburg | Germany | EUR |
| Munich:A89 | Munich | Germany | EUR |
| Stuttgart:A89 | Stuttgart | Germany | EUR |
| Turquoise:ADOCP | Turquoise | United Kingdom | EUR |
Valuation
EV/sales 48.1× against a median of 5.4×: 5th lowest of 6 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- €70.92M EUR
- P/E
- Loss
- EV/sales
- 48.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Adocia SA · EURONEXT:ADOC | US$79.30M | US$77.84M | n/a | 48.1× | n/a | n/a | n/a | n/a | n/a |
| TuHURA Biosciences, Inc. · NASDAQ:HURA | US$82.20M | US$89.50M | n/a | n/a | n/a | 4.3× | n/a | 0.5× | 2.81 |
| 3D Medicines, Inc. · HKEX:1244 | US$81.88M | US$48.38M | n/a | 0.9× | n/a | 1.0× | −49.9% | 0.3× | n/a |
| Kintor Pharmaceutical Ltd · HKEX:9939 | US$81.71M | US$96.98M | n/a | 19.8× | n/a | 5.0× | −612.3% | 1.2× | n/a |
| Nkarta, Inc. · NASDAQ:NKTX | US$81.38M | −US$75.22M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.67 |
| Captor Therapeutics SA · GPW:CTX | US$81.12M | US$64.16M | n/a | 130× | n/a | 5.1× | n/a | 0.0× | n/a |
| Vaxart, Inc. · OTC:VXRT | US$79.89M | US$14.34M | 2.8× | 0.1× | 0.4× | 1.2× | 16.0% | 0.0× | 1.21 |
| Sensorion SAS · EURONEXT:ALSEN | US$79.63M | −US$13.98M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| Tiziana Life Sciences Ltd · NASDAQ:TLSA | US$78.98M | US$76.73M | n/a | n/a | n/a | n/a | n/a | n/a | 1.23 |
| Nyrada, Inc. · ASX:NYR | US$78.76M | US$73.21M | n/a | n/a | n/a | 12.5× | n/a | 0.0× | n/a |
| TiumBio Co., Ltd. · KRX:321550 | US$76.77M | US$60.20M | n/a | 5.4× | n/a | 2.9× | −114.1% | 0.3× | n/a |
| Median of the others | US$80.50M | US$62.18M | 2.8× | 5.4× | 0.4× | 2.9× | −82.0% | 0.0× | 1.45 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 9.45 EUR · Analysts' mean
- EPS, year to Dec 2026
- 0.51 · 2 analysts
- Revenue, year to Dec 2026
- 28.39M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Olivier Soula | Chief Executive Officer |
| Mathieu-William Gilbert | Chief Financial Officer - Chief Operating Officer |
| Alexander Zan Fleming | President |
| David Rigal | Pharmaceutical Operations Director |
| Géraldine Favre Soula | Director of human resources |
Board
| Director | Role |
|---|---|
| Stéphane Boissel | Chairman of the Board |
| Tim Heise | Chairman of the Board of Directors |
| Jacky Vonderscher | Board member |
| Mads Dall | Board member |
| Maureen Deehan | Board member |
| Olivier Soula | Chief Executive Officer |
| Valérie Moumdjian | Board member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Feb 24, 2026 | −1.8% |
| Quarter to Sep 30, 2025 | Oct 15, 2025 | −0.4% |
| Q2 2025 | Sep 29, 2025 | +11.2% |
| Quarter to Mar 31, 2025 | Apr 30, 2025 | +4.8% |
| Quarter to Sep 30, 2024 | Oct 30, 2024 | −4.6% |
| Q2 2024 | Sep 19, 2024 | −0.5% |
| Quarter to Mar 31, 2024 | Apr 24, 2024 · After close | −7.8% |
| Q3 2023 | Oct 25, 2023 · After close | +3.4% |
| Q2 2023 | Sep 18, 2023 · After close | −20.5% |
| Q1 2023 | Apr 25, 2023 · After close | −1.8% |
All 18 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2022 | Mar 15, 2023 · After close | −4.1% |
| Q3 2022 | Oct 25, 2022 · After close | +1.8% |
| Q2 2022 | Sep 20, 2022 · After close | −8.7% |
| Q1 2022 | Apr 26, 2022 · After close | −1.0% |
| Q3 2021 | Oct 26, 2021 | +1.8% |
| Q2 2021 | Sep 7, 2021 | −1.3% |
| Q1 2021 | Apr 21, 2021 | −3.7% |
| Q4 2020 | Mar 18, 2021 | −4.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 19 slides | Nov 2, 2026 |
| Investor Presentation (November 2026) | Investor deck | 33 slides | November 2026 |
| Investor Presentation (June 2026) | Investor deck | 43 slides | June 2026 |
| Investor Presentation (March 2026) | Investor deck | 43 slides | March 2026 |
| Investor Presentation (November 2025) | Investor deck | 42 slides | November 2025 |
| Shareholder Meeting (June 2025) | Shareholder meeting | 85 slides | Jun 11, 2025 |
| Investor Presentation (April 2025) | Investor deck | 30 slides | Apr 1, 2025 |
| Investor Presentation (February 2025) | Investor deck | 30 slides | Feb 18, 2025 |
| Investor Presentation (January 2025) | Investor deck | 30 slides | January 2025 |
| Investir Day 2024 | Conference | 11 slides | November 2024 |
All 49 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2024) | Investor deck | 41 slides | September 2024 |
| Shareholder Meeting (June 2024) | Shareholder meeting | 94 slides | Jun 13, 2024 |
| Investor Presentation (April 2024) | Investor deck | 42 slides | April 2024 |
| Investor Presentation (April 2024) | Investor deck | 42 slides | April 2024 |
| Investor Presentation (April 2024) | Investor deck | 18 slides | April 2024 |
| Investor Presentation (March 2024) | Investor deck | 42 slides | March 2024 |
| Investor Presentation (March 2024) | Investor deck | 42 slides | March 2024 |
| Investor Presentation (January 2024) | Investor deck | 23 slides | January 2024 |
| LSX Investival (November 2023) | Conference | 23 slides | November 2023 |
| Investor Presentation (October 2023) | Investor deck | 42 slides | October 2023 |
| Investor Presentation (October 2023) | Investor deck | 42 slides | October 2023 |
| Shareholder Meeting (May 2023) | Shareholder meeting | 81 slides | May 11, 2023 |
| Investor Presentation (March 2023) | Investor deck | 48 slides | March 2023 |
| Investor Presentation (January 2023) | Investor deck | 48 slides | January 2023 |
| Investor Presentation (January 2023) | Investor deck | 48 slides | January 2023 |
| Investor Presentation (November 2022) | Investor deck | 49 slides | November 2022 |
| Investor Presentation (November 2022) | Investor deck | 49 slides | November 2022 |
| Shareholder Meeting (June 2022) | Shareholder meeting | 71 slides | Jun 15, 2022 |
| Investor Presentation (May 2022) | Investor deck | 43 slides | May 2022 |
| Investor Presentation (April 2022) | Investor deck | 38 slides | April 2022 |
| Investor Presentation (January 2022) | Investor deck | 37 slides | January 2022 |
| Investor Presentation (January 2022) | Investor deck | 39 slides | January 2022 |
| Investor Presentation (October 2021) | Investor deck | 40 slides | October 2021 |
| Investor Presentation (June 2021) | Investor deck | 40 slides | June 2021 |
| Shareholder Meeting (May 2021) | Shareholder meeting | 65 slides | May 20, 2021 |
| Shareholder Meeting (May 2021) | Shareholder meeting | 65 slides | May 20, 2021 |
| Investor Presentation (September 2020) | Investor deck | 28 slides | September 2020 |
| Investor Presentation (January 2020) | Investor deck | 32 slides | January 2020 |
| Shareholder Meeting (May 2019) | Shareholder meeting | 73 slides | May 16, 2019 |
| Investor Presentation (April 2019) | Investor deck | 36 slides | April 2019 |
| Investor Presentation (September 2018) | Investor deck | 36 slides | September 2018 |
| Investor Presentation (June 2018) | Investor deck | 35 slides | June 2018 |
| Shareholder Meeting (May 2018) | Shareholder meeting | 60 slides | May 17, 2018 |
| Investor Presentation (May 2018) | Investor deck | 40 slides | May 2018 |
| Investor Presentation (April 2018) | Investor deck | 39 slides | April 2018 |
| Investor Presentation (January 2018) | Investor deck | 40 slides | January 2018 |
| Investor Presentation (September 2017) | Investor deck | 35 slides | September 2017 |
| Investor Presentation (June 2017) | Investor deck | 32 slides | June 2017 |
| Investor Presentation (April 2012) | Investor deck | 56 slides | April 2012 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| New shares under shareholder loan agreement Tranche closed: convertible Buyers: Vester Finance (shareholder loan of up to €10 million) | Nov 6, 2026 | |
| Private placement of new ordinary shares Announced: €3M · €2.042 a share · Vester Finance Dealers: Vester Finance Buyers: Olivier Soula (2% of the Company’s share capital following completion of the Capital Increase); Vester Finance (6.9% of the Company’s share capital following completion of the Capital Increase) Insiders: All the directors of the Company, including the chief executive officer, participated in the Capital Increase Use of proceeds: Promote BioChaperone technology to sign partnerships, develop AdoXLong platform towards clinic, and general corporate purposes | Oct 20, 2026 | US$3.36M |
| New shares Tranche closed: raise Buyers: Vester Finance (200,000 new shares issued over the month under the shareholder loan agreement) | Aug 24, 2026 | |
| Shareholder loan repayable in new shares Update: up to €6M Buyers: Vester Finance (shareholder loan of up to €6.0 million) Use of proceeds: Extend cash runway until the beginning of Q2 2027 | Apr 21, 2026 | US$7.05M |
| Private placement of new ordinary shares with share warrants attached (ABSAs) Closed: €10M raised · €7.92 a share · Warrants at €9.11 for 42 months · Stifel Europe Securities SAS and Stifel Europe Limited Paris Branch (Stifel) Dealers: Stifel Europe Securities SAS and Stifel Europe Limited Paris Branch (Stifel) (lead) Buyers: CVI Investments, Inc. (subscribed the whole €10 million; 1,262,626 shares, 6.5% of capital post-offering) Use of proceeds: About 50% for the AdoXLong platform, 30% for BioChaperone industrial-scale manufacturing, 20% for working capital | Dec 4, 2025 | US$11.66M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.48M | 9.32M | 2.15M | 11.4M | 1.44M | 841.0K | 2.14M | 47.4M | 19.5M | 22.5M |
| Cost of revenue | 19.4M | 19.1M | 765.0K | 1.84M | 1.26M | 1.46M | 1.71M | 2.19M | 1.74M | 1.78M |
| Gross profit | -17.9M | -9.83M | 1.39M | 9.61M | 180.0K | -616.0K | 437.0K | 45.2M | 17.7M | 20.7M |
| Research and development | 14.2M | 14.5M | 14.8M | 25.9M | 20.0M | 22.5M | 23.3M | 25.8M | 27.1M | 30.4M |
| Selling, general and administrative | 9.61M | 5.48M | 240.0K | 265.0K | 257.0K | 13.1M | 25.6M | 19.0M | 19.1M | |
| Operating income | -15.8M | -7.40M | -14.2M | -1.70M | -19.4M | -21.1M | -22.0M | 9.71M | -42.5M | -8.00M |
| Depreciation and amortization | 601.0K | 654.0K | 508.0K | 496.0K | 1.16M | 1.20M | 1.16M | 1.04M | 1.01M | 740.0K |
| EBITDA | -15.2M | -6.75M | -13.7M | -1.20M | -18.2M | -19.9M | -20.9M | 10.8M | -41.5M | -7.26M |
| Interest expense | 841.0K | 1.01M | 7.00M | 5.30M | 3.61M | 2.07M | 416.0K | 149.0K | 110.0K | 78.0K |
| Income before tax | -16.6M | -8.37M | -21.2M | -6.42M | -22.8M | -23.3M | -21.6M | 11.8M | -8.52M | -7.82M |
| Income tax | -12.0K | 952.0K | 2.00K | 476.0K | 0 | 29.0K | -2.96M | 4.14M | 35.0K | 72.0K |
| Net income | -16.6M | -9.32M | -21.2M | -6.90M | -22.8M | -23.3M | -18.6M | 7.62M | -8.55M | -7.89M |
| Earnings per share, basic | -0.90 | -0.60 | -1.90 | -0.90 | -3.20 | -3.34 | -2.68 | 1.00 | -1.25 | -1.15 |
| Earnings per share, diluted | -0.90 | -0.60 | -1.90 | -0.90 | -3.20 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.3M | 7.53M | 13.0M | 17.4M | 15.2M | 28.1M | 43.7M | 39.8M | 34.8M | 58.0M |
| Short-term investments | -1.00K | -1.00K | -1.00K | -1.00K | ||||||
| Receivables | 145.0K | 8.60M | 111.0K | 467.0K | 207.0K | 6.61M | 7.01M | 12.2M | 328.0K | 11.4M |
| Inventory | 362.0K | 220.0K | 132.0K | 137.0K | 517.0K | 569.0K | 181.0K | 131.0K | 99.0K | 66.0K |
| Current assets | 23.9M | 22.4M | 20.2M | 26.3M | 22.1M | 36.4M | 52.2M | 61.0M | 44.7M | 70.0M |
| Property, plant and equipment | 3.12M | 3.17M | 2.85M | 967.0K | 8.53M | 9.54M | 8.73M | 8.97M | 8.45M | |
| Goodwill | 0 | 0 | ||||||||
| Total assets | 28.5M | 27.0M | 25.0M | 30.6M | 30.1M | 45.2M | 62.0M | 70.0M | 53.8M | 78.8M |
| Accounts payable | 2.84M | 3.53M | 3.97M | 6.41M | 3.83M | 2.43M | 2.65M | 3.66M | 1.62M | 1.74M |
| Current liabilities | 20.0M | 20.9M | 19.8M | 25.1M | 23.8M | 10.7M | 11.2M | 14.9M | 8.88M | 28.0M |
| Long-term debt | 0 | 1.95M | 4.54M | 17.5M | 18.3M | 25.2M | 18.5M | 4.89M | 5.78M | 6.28M |
| Total debt | 8.90M | 11.8M | 13.1M | 33.2M | 34.5M | 28.2M | 21.2M | 7.12M | 7.57M | 7.07M |
| Total liabilities | 27.0M | 30.1M | 31.9M | 43.6M | 43.9M | 38.8M | 33.9M | 24.2M | 16.9M | 36.0M |
| Shareholders' equity | 1.49M | -3.09M | -6.91M | -13.0M | -13.8M | 6.33M | 28.0M | 45.8M | 36.9M | 42.8M |
| Shares outstanding | 19.6M | 15.7M | 14.1M | 8.73M | 7.27B | 6.97M | 6.94M | 7.62M | 6.86M | 6.85M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -6.53M | -15.6M | -4.95M | -15.0M | -19.2M | -21.9M | -9.65M | 6.31M | -22.2M | -13.1M |
| Capital spending | -267.0K | -229.0K | -156.0K | -153.0K | -361.0K | -205.0K | -2.02M | -784.0K | -1.98M | -8.08M |
| Free cash flow | -6.80M | -15.8M | -5.11M | -15.1M | -19.6M | -22.1M | -11.7M | 5.53M | -24.2M | -21.2M |
| Cash from investing | -275.0K | -258.0K | -138.0K | 21.9M | -361.0K | -204.0K | -2.05M | -1.03M | -1.69M | -7.19M |
| Cash from financing | 16.5M | 10.4M | 629.0K | -4.61M | 6.64M | 6.51M | 15.5M | -216.0K | 653.0K | 6.30M |
| Share buybacks | 12.1M | 7.87M | 0 | 1.04M | 0 | 0 | 2.00K | 40.0K | 4.00K | |
| Change in cash | 9.72M | -5.43M | -4.46M | 2.26M | -13.0M | -15.5M | 3.82M | 5.06M | -23.3M | -14.0M |
Cap table
Built by 6ix from Adocia SA’s releases · as of Nov 6, 2026
- Common shares
- 21,937,614
- Fully diluted
- 21,937,614
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 21,937,614 | Aug 24, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · €9.11 · expire about Jun 2029 |
Share count over time
| Count | Shares |
|---|---|
| Aug 24, 2026 | 21,937,614 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alexander Zan Fleming | President · Since at least Nov 4, 2026 |
| Dan Einhorn | Since at least Nov 4, 2026 |
| David Rigal | Pharmaceutical Operations Director · Since at least Nov 5, 2026 |
| Ekaterina Smirnyagina | Director · Until Sep 1, 2026 · Past |
| Géraldine Favre Soula | Director of human resources · Since at least Nov 5, 2026 |
| Jacky Vonderscher | Board member · Since at least Sep 24, 2026 |
| Mads Dall | Board member · Since at least Nov 5, 2026 |
| Mathieu-William Gilbert | Chief Financial Officer - Chief Operating Officer · Since at least Oct 29, 2026 |
| Maureen Deehan | Board member · Since at least Oct 29, 2026 |
| Olivier Soula | Chief Executive Officer · Since at least Oct 29, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Stéphane Boissel | Chairman of the Board · Since at least Oct 20, 2026 |
| Tim Heise | Chairman of the Board of Directors · Since at least Sep 24, 2026 |
| Valérie Moumdjian | Board member · Since at least Sep 25, 2025 |
Log in to ask 6ix AI your own questions about Adocia SA.